

**Plasma 25-hydroxyvitamin D concentration and risk of islet autoimmunity**

Short running title: 25(OH)D and Islet Autoimmunity

Jill M. Norris, PhD<sup>1</sup>, Hye-Seung Lee, PhD<sup>2</sup>, Brittni Frederiksen, PhD<sup>1</sup>, Iris Erlund, PhD<sup>3</sup>, Ulla Uusitalo, PhD<sup>2</sup>, Jimin Yang, PhD<sup>2</sup>, Åke Lernmark, PhD<sup>4</sup>, Olli Simell, PhD<sup>5</sup>, Jorma Toppari, PhD<sup>5,6</sup>, Marian Rewers, PhD<sup>7</sup>, Anette-G. Ziegler, PhD<sup>8</sup>, Jin-Xiong She, PhD<sup>9</sup>, Suna Onengut-Gumuscu, PhD<sup>10</sup>, Wei-Min Chen, PhD<sup>10</sup>, Stephen S. Rich, PhD<sup>10</sup>, Jouko Sundvall, MS<sup>3</sup>, Beena Akolkar, PhD<sup>11</sup>, Jeffrey Krischer, PhD<sup>2</sup>, \*Suvi M. Virtanen, PhD<sup>12</sup>, \*William Hagopian, PhD<sup>13</sup> and  
for the TEDDY Study Group

\*Co-senior authors

<sup>1</sup>Department of Epidemiology, Colorado School of Public Health, University of Colorado  
Anschutz Medical Campus, Aurora, CO, USA

<sup>2</sup>Health Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa,  
FL, USA

<sup>3</sup>Department of Health, Genomics and Biomarkers Unit, National Institute for Health and  
Welfare, Helsinki, Finland

<sup>4</sup>Department of Clinical Sciences, Lund University/CRC, Malmö, Sweden

<sup>5</sup>Department of Pediatrics, Turku University Hospital, Turku, Finland.

<sup>6</sup>Department of Physiology, Institute of Biomedicine, University of Turku, Turku, Finland.

<sup>7</sup>Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, CO,  
USA

<sup>8</sup>Department of Pediatrics, Diabetes Research Institute, Munich, Germany

<sup>9</sup>Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, GA, USA

<sup>10</sup>Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA

<sup>11</sup>National Institutes of Diabetes and Digestive and Kidney Disorders, National Institutes of  
Health, Bethesda, MD, USA

<sup>12</sup>National Institute for Health and Welfare, Nutrition Unit, Helsinki; University of Tampere,  
School of Health Sciences; Center for Child Health Research, University of Tampere and  
Tampere University Hospital; and The Science Center of Pirkanmaa Hospital District, Tampere,  
Finland

<sup>13</sup>Pacific Northwest Diabetes Research Institute, Seattle, WA, USA

Corresponding author: Jill M. Norris, MPH, PhD, Colorado School of Public Health, 13001 East  
17<sup>th</sup> Place, Box B119, Aurora, Colorado 80045. Email: [jill.norris@ucdenver.edu](mailto:jill.norris@ucdenver.edu). Phone: 303-  
724-4428

Word Count: 3796

Number of Tables: 3

Number of Figures: 1

Key words: autoantibodies, vitamin D, 25,hydroxyvitamin D, single nucleotide polymorphisms,  
type 1 diabetes, interaction

## Abstract

We examined the association between plasma 25-hydroxyvitamin D (25[OH]D) concentration and islet autoimmunity(IA); and whether vitamin D gene polymorphisms modify the effect of 25(OH)D on IA risk. We followed 8676 children at increased genetic risk of type 1 diabetes(T1D) at 6 sites in the US and Europe. We defined IA as positivity for at least one autoantibody (GADA, IAA or IA-2A) on 2 or more visits. We conducted a risk-set sampled nested case-control study of 376 IA cases and up to 3 controls per case. 25(OH)D concentration was measured on all samples prior to, and including the first IA positive visit. Nine polymorphisms in *VDR*, *CYP24A*, *CYP27B1*, *GC*, and *RXRA* were analyzed as effect modifiers of 25(OH)D. Adjusting for HLA-DR-DQ and ancestry, higher childhood 25(OH)D was associated with lower IA risk (odds ratio(OR): 0.93 for a 5 nmol/L difference; 95% confidence interval(CI): 0.89,0.97). Moreover, this association was modified by *VDR* rs7975232 (interaction  $p=0.0072$ ), where increased childhood 25(OH)D was associated with a decreasing IA risk based upon number of minor alleles: 0 (OR:1.00; CI:0.93,1.07), 1 (OR:0.92; CI:0.89,0.96), and 2 (OR:0.86; CI:0.80,0.92). Vitamin D and *VDR* may have a combined role in IA development in children at increased genetic risk for T1D.

## Introduction

Type 1 diabetes is a chronic autoimmune disease with increasing incidence worldwide, and a geographical gradient in risk where incidence is higher at higher latitudes.(1) Vitamin D represents a candidate protective factor for type 1 diabetes as it regulates the immune system and autoimmunity,(2) and vitamin D status varies by latitude.(3) Vitamin D supplementation in infancy may be associated with a lower risk of type 1 diabetes(4), yet there is substantial heterogeneity across studies.(5) Moreover, dietary intake of vitamin D (from food and supplements) throughout childhood has not been found to be associated with either islet autoimmunity (IA) or the progression from IA to type 1 diabetes.(6)

Previous studies are limited in that dietary intake is only one of a number of determinants of circulating 25-hydroxyvitamin D (25[OH]D), an established marker of vitamin D status that may more accurately reflect vitamin D exposure. While 25(OH)D levels are lower in individuals with type 1 diabetes at diagnosis compared with controls,(7; 8) it is unclear whether levels are lower prior to diagnosis. Serum 25(OH)D levels in pregnancy(9; 10) and at birth(11; 12) are not consistently associated with development of IA or type 1 diabetes in the offspring. While one cross-sectional analysis showed lower 25(OH)D concentrations in a young cohort of IA positive subjects compared with IA negative subjects,(13) another showed no difference in 25(OH)D level by IA positivity.(14) In prospective studies of children at increased risk for type 1 diabetes, 25(OH)D levels were not associated with IA development or progression to type 1 diabetes.(6; 15) Yet, adult-onset type 1 diabetes subjects had lower 25(OH)D levels prior to diagnosis than controls,(16; 17) suggesting a protective effect in adult-onset disease.

These discrepant results may be due to features of study designs, population variation in 25(OH)D levels, and/or a failure to account for underlying genetic variation in the vitamin D

pathway. A number of genes play a role in transporting 25(OH)D and 1,25(OH)<sub>2</sub>D (notably *GC*, which encodes the vitamin D binding protein), converting 25(OH)D to 1,25(OH)<sub>2</sub>D (*CYP27B1*), degradation of 1,25(OH)<sub>2</sub>D (*CYP24A1*), as well as enabling the action of 1,25(OH)<sub>2</sub>D (*VDR* and *RXRA*). The *VDR* gene encodes the vitamin D receptor, which forms a heterodimer with the retinoid X receptor  $\alpha$ , encoded by *RXRA*. In the presence of 1,25(OH)<sub>2</sub>D, this heterodimer binds to Vitamin D response elements (VDRE) at many loci, altering gene expression in a number of biological pathways to influence disease risk. For example there is a VDRE influencing HLA-DRB1 gene expression. Variation in genes in the vitamin D pathway may modify the effectiveness of 25(OH)D concentration. In The Environmental Determinants of Diabetes in the Young (TEDDY), we examined whether 25(OH)D concentration in early infancy and throughout childhood, is associated with development of IA. We hypothesized that the association between 25(OH)D concentration and IA is modified by genetic variants in the vitamin D metabolism pathway.

## Methods

TEDDY is a prospective study of children at increased risk of type 1 diabetes, conducted in centers in the U.S. (Colorado, Georgia/Florida, Washington State) and Europe (Finland, Germany, and Sweden). Detailed study design and methods have been previously published.<sup>(18)</sup> Institutional Review Board approval and written informed consent was obtained for all children. The study is monitored by an External Evaluation Committee formed by the U.S. National Institutes of Health.

TEDDY Cohort

Between September 2004-February 2010, a total of 424,788 newborn infants were screened for type 1 diabetes-associated HLA genotypes.(19) The initial screening identified 21,589 eligible infants, of whom 8,676 were enrolled in the follow-up study before age 4 months.

Infants from the general population (GP), with no first-degree relative with type 1 diabetes, were eligible if they had any one of the following HLA-DR-DQ genotypes: [1] DR3-DQ2/DR4-DQ8, [2] DR4-DQ8/DR4-DQ8, [3] DR4-DQ8/DR8-DQ4, or [4] DR3-DQ2/ DR3-DQ2. Infants with a first-degree relative with type 1 diabetes (FDR) were eligible with any above genotype or with [5] DR4-DQ8/DR4-DQ2.3, [6] DR4-DQ8/DR1-DQB 5.1, [7] DR4-DQ8/DR13-DQ6.4, [8] DR4-DQ8/DR9-DQ9.3, or [9] DR3-DQ2/DR9-DQ9.3. These HLA-DR-DQ genotypes are referred to in the text by abbreviated names listing only DR/DR genotypes (HLA-DR3/4, is defined as [1] above).

Clinic visits occurred every 3 months between 3 to 48 months of age, and every 6 months thereafter. The child's weight and height (or length) were measured at each visit. Participants who lived far from the TEDDY clinic were placed on a "long distance protocol" (LDP) which permitted remote sampling with shipment overnight to the research clinic.

Serum autoantibodies to glutamate decarboxylase (GADA), insulinoma antigen-2(IA-2A), and insulin (IAA) were measured in two harmonized core laboratories using radiobinding assays incorporating extensive quality control.(20; 21) Positive results due to maternal IgG transmission were removed. Persistent IA was defined as positive antibodies to the same antigen confirmed by both core laboratories in two consecutive samples, with the date of seroconversion defined as that of the first positive sample.

Nested Case-Control Study

We conducted a nested case-control study using risk set sampling, as described previously,(22) using data collected as of May 31, 2012. Briefly, 418 persistent IA cases were identified and 3 controls per case were selected. A control was a participant who had not developed persistent IA by the time the case to which it is matched had developed IA, within  $\pm 45$  days of the event time. Matching factors were clinical center, sex, and family history of type 1 diabetes to control for differences in geographic area, genetic background and in sample/data handling between clinical centers.

### 25(OH)D Measurement

Plasma from blood drawn into light-protected tubes at all visits up to the event time in cases and controls were sent to the Genomics and Biomarkers Unit, National Institute for Health and Welfare, Helsinki, Finland. There, 25(OH)D concentrations were measured using the ARCHITECT 25-OH Vitamin D chemiluminescent micro particle immunoassay (CMIA). The assay was standardized against calibrators traceable to internal reference material (Sigma17938). Precision within the project, expressed as the coefficient of variation for four different external quality control samples included in each run, at concentration range 40.2-96.0 nmol/L, was 3.6-4.8%. The respective values for four internal control samples at concentration range 37.9-104.4 nmol/L was 2.7-4.8%. The laboratory was blinded to the external quality control samples and case-control status. The laboratory participates regularly in DEQAS (Vitamin D External Quality Assessment Scheme); during this project, mean bias $\pm$ SD from the ALTM(all-laboratory trimmed mean) for the participating laboratories was  $3.8 \pm 5.6\%$  (n=14), and mean bias $\pm$ SD from NIST target value was  $-5.0 \pm 8.7\%$  (n=14) for samples ranging between 24.5-98.4 nmol/L.

The ARCHITECT CMIA method is a high through-put method with excellent reproducibility and is commonly used in clinical laboratories. The method requires about 10  $\mu$ l of sample,



making it an attractive choice in children's studies, where limited sample volumes are available. Furthermore it is relatively inexpensive. The reference method for 25(OH)D determination is based on LC-MS/MS, which is more specific and allows the separation of different isomers of vitamin D as well as measuring low levels of them (including 1,25-dihydroxyvitamin D). Also, additional variability in results, potentially caused by differences in vitamin D binding protein levels, observed in pregnant women, or high urea levels in hemodialysis patients, are avoided. These issues are, however, irrelevant in TEDDY. Therefore, because of excellent suitability for high through-put analysis, the low sample amount required, the excellent reproducibility of the method, and lack of any clinically interfering states, the ARCHITECT assay was chosen. Excellent agreement of the method with LC-MS/MS in the concentration range relevant to this study (slope 1.02 up to 80 nmol/L) was previously shown in population samples.(23)

#### Vitamin D Gene Genotyping

Single nucleotide polymorphisms(SNP) were genotyped using the Illumina Infinium ImmunoChip, a custom genotyping array of 195,806 SNPs selected for associations with autoimmune disease. SNPs with call rates <90% or allele distributions strongly deviating from Hardy-Weinberg equilibrium in controls ( $p < 10^{-6}$ ) (except for the HLA region) were discarded. Individuals with call rates <95%, or those discordant with reported sex or prior genotyping, were also discarded.

In order to estimate ancestry, we performed a principal components analysis (PCA) with the ImmunoChip data on the entire TEDDY cohort, after selecting one subject per family, using EIGENSTRAT software.

For purposes of our targeted hypothesis regarding the vitamin D gene pathway and the effect of 25(OH)D, we identified SNPs in *GC*(rs7041), *VDR* [rs1544410(BsmI), rs731236(TaqI),

rs11568820(Cdx2), rs7975232(ApaI)], *CYP27B1*(rs10877012, rs4646536), *CYP24A1* (rs4809959, rs2616277), and *RXRA*(rs3818740, rs10881582). rs731236 and rs10877012 were removed from analysis as they were in complete linkage disequilibrium with rs1544410 and rs4646536, respectively.

### Statistical Analyses

Children who were missing either 25(OH)D levels or vitamin D gene data were excluded from analysis, resulting in 376 cases and 1,041 controls (297 cases with 3 controls, 71 cases with 2 controls and 8 cases with 1 control). The median age at seroconversion in cases was 21 months (min=2, Q1=12, Q3=31, max=72). The children had 25(OH)D measures on multiple time-points prior to and including the seroconversion visit (min=1; Q1=2; median= 3; Q3=4.5; max=8). Conditional logistic regression was used to compare cases and matched controls, adjusting for HLA genotype and the first two principal components (PC) from the PCA described previously, in order to adjust for ancestry.

We identified factors influencing 25(OH)D concentration in our controls (supplemental table 1), to determine factors for adjustment to remove extraneous variation. We first explored taking the slope of 25(OH)D concentration over all time-points in each child, as a measure of change in 25(OH)D over time. The subject-specific random slopes and random intercepts were generated from a linear mixed effects model of 25(OH)D concentration at all time points, adjusting for season of blood draw, age of blood draw, year of blood draw, height, weight, LDP and sample set. Conditional logistic regression analysis, adjusting for HLA-DR3/4 status, showed that the adjusted slope of 25(OH)D concentration was not different between cases and controls (OR: 0.87; CI: 0.36-2.10), suggesting that change in 25(OH)D over time was not associated with IA. Hence, assuming a constant 25(OH)D in each child, we then calculated an average 25(OH)D

concentration over all time-points in each child ('childhood 25(OH)D concentration') as a summary exposure variable. We created an 'adjusted' 25(OH)D variable by regressing 25(OH)D concentration on the visit-level variables listed in supplemental table 1 using a general linear model. Residuals for each time-point were obtained, and the averaged residual was compared between case and matched controls using conditional logistic regression adjusting for HLA-DR3/4 status and two PCs indicating ancestry. The adjusted childhood average 25(OH)D residual produced a similar association (OR: 0.94 CI: 0.90-0.98) to that obtained with measured 25(OH)D concentration (Table 2; OR: 0.93, CI: 0.89-0.97), suggesting that accounting for visit-level variables such as season of blood collection was not necessary. We therefore continued our analysis with the measured 25(OH)D concentration for increased interpretability.

As previous studies have suggested the importance of early exposure,(5) we examined 25(OH)D in early infancy by using the concentration at the first visit ('early infancy 25(OH)D concentration'). The first 25(OH)D measure was at 3 months of age in 68%, 6 months in 20%, 9 months in 7%, and  $\geq 12$  months in 5% of the children. Only those children whose first visit occurred before 12 months are included in the early infancy 25(OH)D analysis, resulting in 360 cases and their controls (269 cases with three controls, 83 cases with two controls and eight cases with one control). In this analysis, we adjusted for season and age at the first sample, in addition to HLA and ancestry.

Log-linearity of the childhood 25(OH)D concentration and IA association was examined by plotting cumulative martingale residuals(24); the supremum test showed no indication of violating log-linearity, suggesting that it is appropriate to analyze 25(OH)D concentration as a continuous variable. However, given that the US Institute of Medicine(25) and European guidelines(26) suggest that 25(OH)D concentrations  $\geq 50$  nmol/L are optimal, we also

categorized 25(OH) concentration based on this cut-point, and defined childhood vitamin D sufficiency as an average 25(OH)D concentration over all time-points of  $\geq 50$  nmol/L. Early infancy vitamin D sufficiency was defined as the first measured 25(OH)D concentration  $\geq 50$  nmol/L. Average childhood 25(OH)D concentration was within the sufficient range(25; 26) in 58% of the children, whereas in early infancy, 49% of the children were vitamin D sufficient. As the Endocrine Society recommends attaining a 25(OH)D concentration above 75 nmol/L(27), in an exploratory analysis, we further divided the vitamin D sufficiency variable into 50-75 nmol/L and  $> 75$  nmol/L in order to examine whether the higher cut-off provides additional information regarding risk. Average childhood 25(OH)D was above 75 nmol/L in 10% of the children, whereas in early infancy, 12% of the children had 25(OH)D  $>75$  nmol/L.

We tested for an interaction between 25(OH)D concentration and clinical center; the interaction term was not significant suggesting that the association between 25(OH)D and IA did not differ by TEDDY clinical center. All analyses were performed using SAS, Version 9.4. Two-sided p-value $<0.05$  was considered statistically significant.

When examining our *a priori* proposed 25(OH)D\*vitamin D gene interactions, each SNP was analyzed additively by treating the number of minor alleles as a continuous variable. False discovery rate adjusted p-values are also reported for multiple testing correction for 9 SNPs(28).

## Results

The childhood and early infancy mean 25(OH)D concentrations of the cases and controls by the matching variables are shown in table 1. Adjusting for HLA-DR3/4 and the first two PCs indicating ancestry, higher 25(OH)D concentrations throughout childhood and in early infancy were associated with lower IA risk (table 2). Moreover, being vitamin D sufficient in childhood was associated with a 31% lower risk of IA compared with those that were insufficient.

Similarly, early infancy vitamin D sufficiency was associated with a 40% lower risk of IA compared with those who were insufficient. When we further categorize the vitamin D sufficiency variable into 50-75 nmol/L and >75 nmol/L and compare these categories to vitamin D insufficiency (< 50 nmol/L), we find a consistent inverse association between vitamin D status and IA at both the lower and higher categories of sufficiency (supplemental table 2), suggesting that further categorization of our vitamin D sufficiency variable is not informative. Therefore, our remaining analyses are conducted using 25(OH)D as a continuous variable and as a dichotomous vitamin D sufficiency variable, as previously defined.

In a secondary analysis in which we restricted the case definition to those who had multiple autoantibodies, which is strongly predictive of type 1 diabetes,(29) we show similar statistically significant inverse associations between vitamin D and the outcome of multiple autoantibodies (table 2).

Our *a priori* hypothesis was that the association between 25(OH)D and IA would be modified by SNPs in the vitamin D metabolism genes. We detected significant interactions between the *VDR* SNP rs7975232 and childhood and early infancy 25(OH)D concentration (interaction p-value: 0.0072, 0.0019, respectively) and childhood and early infancy vitamin D sufficiency (interaction p-value: 0.01, 0.0051, respectively), adjusting for the HLA-DR3/4 and ancestry (table 3). The association between childhood 25(OH)D and IA was modified by rs7975232 where for each additional minor allele, increased 25(OH)D concentration was associated with a greater decreased IA risk (Figure 1). A similar relationship was seen for early infancy 25(OH)D concentration. The inverse association between vitamin D sufficiency and IA is absent in those with no minor alleles and becomes stronger with each additional allele; in those with 2 minor

alleles, being vitamin D sufficient in childhood or in early infancy was associated with a 59% and 67% (respectively) lower risk of IA compared with those that were insufficient.

In our secondary analysis using only those with multiple autoantibodies for our cases, we detected similar interactions between rs7975232 and childhood 25(OH)D concentration (interaction  $p=0.0199$ ), early infancy 25(OH)D concentration (interaction  $p=0.0055$ ), childhood vitamin D sufficiency (interaction  $p=0.0065$ ), and early infancy vitamin D sufficiency (interaction  $p=0.0111$ ) on IA risk.

## Discussion

In this large prospective study of children at increased type 1 diabetes risk, we found that higher plasma 25(OH)D concentration is associated with a decreased risk of IA. The inverse association was seen when considering the entire cohort, but upon further analysis was primarily seen in those carrying a specific variant in the *VDR* gene. These relationships remained after limiting our cases to those with multiple autoantibodies, a case definition that is strongly predictive of type 1 diabetes(29). Our data suggest that vitamin D level and *VDR* may have a combined role in conferring risk of developing IA, suggesting that the underlying mechanism involves vitamin D action.

Genetic modification of the effect of 25(OH)D may offer an explanation for the inconsistencies in the evidence regarding the putative protective role of vitamin D in type 1 diabetes. Our observation that increasing 25(OH)D concentration was associated with decreased IA risk only in those with minor alleles at *VDR* rs7975232 is novel and suggests that this underlying susceptibility may be related to the ability to adequately use vitamin D. The previous studies of at-risk children that failed to find an association between 25(OH)D and either IA or type 1 diabetes(6; 15) had not explored interactions between 25(OH)D and *VDR* variants. Previous

studies also had fewer IA cases than TEDDY, perhaps resulting in reduced power to detect the relatively small effect size that is observed when not accounting for the interaction.

Vitamin D acts through the vitamin D receptor encoded by the *VDR* gene. Functional *VDR* variants act within a complex gene network conferring greater gene activity in part via enhanced gene transcription or mRNA stability, ultimately modulating expression of *VDR* target genes(30) through vitamin D response elements (VDRE). The genetic information in our study was derived from SNPs measured in an array platform, which incompletely characterize the target genes and cannot precisely identify potential causal variants. In addition, we lack functional data to explore why and how the identified *VDR* variants may modify 25(OH)D associations.

Nevertheless, rs7975232 represents the *Apa1* RFLP, one of three non-functional variants (*Bsm1*, *Apa1*, and *Taq1*) that are in linkage disequilibrium with each other and with the polyA VNTR in the 3'UTR of *VDR*, which helps regulate gene expression. PolyA variants (falling into a bimodal distribution of short and long polyA regions) are associated with differences in *VDR* activity.(31) The *Bsm1*-*Apa1*-*Taq1* haplotype containing the *Apa1*(rs7975232) minor allele (linked to the short polyA region) appears to display better vitamin D response, as measured by in vivo response to calcitriol treatment and serum osteocalcin levels.(30) This is consistent with our finding that the effect of 25(OH)D concentration is more pronounced in those with minor alleles at rs7975232.

While we do not have a measure of the more biologically active 1,25(OH)<sub>2</sub>D<sub>3</sub> in the TEDDY children, circulating 25(OH)D concentration has been shown to predict levels of 1,25(OH)<sub>2</sub>D<sub>3</sub>(32; 33). The vitamin D binding protein (VDBP), which transports 25(OH)D to the kidney for conversion to 1,25(OH)<sub>2</sub>D, likely plays an important role in the body's ability to use 25(OH)D effectively. Although we did not measure VDBP levels in TEDDY, we found that

25(OH)D concentration did not interact with rs7041 in *GC* (the gene that encodes VDBP) on the risk of IA (see table 3).

The epidemiological data suggest a possible scenario where greater VDR activity for a given amount of 1,25(OH)<sub>2</sub>D could provide protection in situations of low 25(OH)D. For example, the Bsm1 BB genotype was associated with type 1 diabetes risk only in environments of high 25(OH)D levels.(36) In another autoimmune disease, systemic lupus erythematosus (SLE), *CYP24A1*rs4809959 modified the effect of 25(OH)D, where for each additional minor allele, increased 25(OH)D was associated with further decreased SLE risk.(37) Low 25(OH)D concentration was associated with a composite outcome of incident hip fracture, myocardial infarction, cancer and mortality, only in those who had one or more minor allele at *VDR* loci.(38) Other studies have found a combined effect of VDR variants and 25(OH)D on risk of breast cancer (Bsm1),(39) prostate cancer (Cdx2),(40) and asthma (Taq1).(41)

1,25(OH)<sub>2</sub>D<sub>3</sub> autoregulates the expression of the VDR gene in target cells(34; 35), and nearly all immune cells express the VDR, suggesting a plausible mechanism by which 1,25(OH)<sub>2</sub>D<sub>3</sub> is immunomodulatory. 1,25(OH)<sub>2</sub>D<sub>3</sub> has both pro- and anti-inflammatory actions, which may be particularly important for autoimmune disease. As monocytes differentiate into dendritic cells, 1,25(OH)<sub>2</sub>D<sub>3</sub> pushes them towards a tolerogenic state characterized by anti-inflammatory IL10 dominance over pro-inflammatory cytokines such as IL12 and TNFα. Conversely, 1,25(OH)<sub>2</sub>D<sub>3</sub> stimulates the initial differentiation of monocytes into pro-inflammatory macrophages producing IL1B and cathelicidin for effective pathogen clearance. However, 1,25(OH)<sub>2</sub>D<sub>3</sub> subsequently decreases macrophage production of a variety of pro-inflammatory factors while increasing anti-inflammatory IL-10 to restore macrophage balance [reviewed in (42)]. Taken in total, these



actions are consistent with decreased autoimmunity without compromising immune defense against pathogens.

1,25(OH)<sub>2</sub>D promotes immune tolerance by not only shifting the balance of the body's T-cell response from Th1 to a Th2 response, but also by maintaining B cell homeostasis,[reviewed in(43)] and thus may decrease the risk of autoimmune diseases such as type 1 diabetes. Vitamin D deficiency in early life led to an earlier onset and higher risk of diabetes in the genetically-predisposed NOD mouse(44). Likewise, treatment with 1,25(OH)<sub>2</sub>D<sub>3</sub> or its structural analogs may result in a decrease in insulinitis and diabetes development in NOD mice [reviewed in(45)]. However, in humans, low dose 1,25(OH)<sub>2</sub>D offered little improvement on insulin requirements in new onset subjects,(46; 47) although this may have been because treatment occurred too late in the disease process.

While we had adequate power to detect the described interaction between 25(OH)D and *VDR*, other genetic interactions of smaller magnitude might be missed here, and would require even larger studies for detection. We were not able to examine the association between IA and vitamin D deficiency, as only 6% of the children in our nested case control study were vitamin D deficient, as defined by average childhood 25(OH)D concentration < 30 nmol/L. Moreover, we cannot exclude the possibility that 25(OH)D concentration may be marking confounding variables such as a different lifestyle, social class or eating habits.

Vitamin D insufficiency (ie, 25(OH)D concentration < 50nmol/L) is relatively common, detected in 42% of the at-risk children in TEDDY, and in 22-67% of new onset type 1 diabetes patients(48-50). Although ours is an observational study, our results suggest that attaining vitamin D sufficiency in children at risk for developing type 1 diabetes may have a protective

role. Interventions in infants and children via vitamin D supplementation(51) or dietary modification(52) have been successful in attaining vitamin D sufficiency. Whether or not these efforts should target children who have specific variants in the *VDR* gene requires further investigation.

In conclusion, this study indicates that higher concentration of circulating 25(OH)D in combination with *VDR* genotype, may decrease risk of IA in children who are at increased risk for type 1 diabetes, as defined by HLA genotype or family history of type 1 diabetes. Further studies are needed to confirm these associations, and to enhance knowledge of how variation in vitamin D metabolism genes may alter individual responsiveness to vitamin D. Measurement of an individual's vitamin D status, along with genetic variation within vitamin D metabolism genes, may help identify individuals most responsive to intervention.

### **Acknowledgements**

Author contributions: J.M.N. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs. Hagopian and Virtanen contributed equally to this study.

*Study concept and design:* Norris, Lernmark, Rewers, She, Simell, Toppari, Ziegler, Akolkar, Krischer, Erlund, Frederiksen, Hagopian, Virtanen

*Acquisition, analysis or interpretation of data:* Norris, Lee, Frederiksen, Erlund, Uusitalo, Yang, Onengut-Gumuscu, Chen, Rich, Sundvall, Lernmark, Rewers, She, Simell, Toppari, Ziegler, Krischer, Hagopian, Virtanen

*Drafting of the manuscript:* Norris

*Critical revision of the manuscript for important intellectual content:* Lee, Frederiksen, Erlund, Uusitalo, Yang, Onengut-Gumuscu, Chen, Rich, Sundvall, Lernmark, Rewers, She, Simell, Toppari, Ziegler, Akolkar, Krischer, Hagopian, Virtanen

*Statistical analysis:* Lee, Krischer, Rich, Chen

*Obtained funding:* Lernmark, Rewers, Hagopian, She, Simell, Toppari, Ziegler, Krischer

*Administrative, technical, or material support:* Chen, Sundvall, Erlund, Rich, Onengut-Gumuscu, Rewers, Hagopian, Simell, Toppari, Ziegler, Krischer, Hagopian, Virtanen

*Study supervision:* Norris, Rewers, Lernmark, She, Toppari, Ziegler, Krischer, Hagopian, Virtanen.

**Declaration of Interests:** We declare no competing interests.

**Funding:** This work is funded by U01 DK63829, U01 DK63861, U01 DK63821, U01 DK63865, U01 DK63863, U01 DK63836, U01 DK63790, UC4 DK63829, UC4 DK63861, UC4 DK63821, UC4 DK63865, UC4 DK63863, UC4 DK63836, UC4 DK95300, UC4 DK100238, UC4 DK106955, and Contract No. HHSN267200700014C from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), Juvenile Diabetes Research Foundation (JDRF), and Centers for Disease Control and Prevention (CDC). This work was supported in part by the NIH/NCATS Clinical and Translational Science Awards to the University of Florida (UL1 TR000064) and the University of Colorado (UL1 TR001082).

**Role of the Funding Source:** The funders of this study were represented on the Steering Committee and played a role in the design and conduct of the study; collection, management,

analysis and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

## References

1. Tuomilehto J: The emerging global epidemic of type 1 diabetes. *Current Diabetes Reports* 2013;13:795-804
2. Rosen Y, Daich J, Soliman I, Brathwaite E, Shoenfeld Y: Vitamin D and autoimmunity. *Scand J Rheumatol* 2016;45:439-447
3. Kimlin MG: Geographic location and vitamin D synthesis. *Molec Aspects Med* 2008;29:453-461
4. Hyppönen E, Läärä E, Reunanen A, Järvelin M-R, Virtanen SM: Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. *The Lancet* 2001;358:1500-1503
5. Dong JY, Zhang WG, Chen JJ, Zhang ZL, Han SF, Qin LQ: Vitamin d intake and risk of type 1 diabetes: a meta-analysis of observational studies. *Nutrients* 2013;5:3551-3562
6. Simpson M, Brady H, Yin X, Seifert J, Barriga K, Hoffman M, Bugawan T, Baron AE, Sokol RJ, Eisenbarth G, Erlich H, Rewers M, Norris JM: No association of vitamin D intake or 25-hydroxyvitamin D levels in childhood with risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY). *Diabetologia* 2011;54:2779-2788
7. Pozzilli P, Manfredi S, Crino A, Picardi A, Leomanni C, Cherubini V, Valente L, Khazrai M, Visalli N, Group I: Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes. *Horm Metab Res* 2005;37:680-683
8. Littorin B, Blom P, Schölin A, Arnqvist HJ, Blohmé G, Bolinder J, Ekbom-Schnell A, Eriksson JW, Gudbjörnsdóttir S, Nyström L, Östman J, Sundkvist G: Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). *Diabetologia* 2006;49:2847-2852
9. Miettinen ME, Reinert L, Kinnunen L, Harjutsalo V, Koskela P, Surcel H-M, Lamberg-Allardt C, Tuomilehto J: Serum 25-hydroxyvitamin D level during early pregnancy and type 1 diabetes risk in the offspring. *Diabetologia* 2012;55:1291-1294
10. Sorensen IM, Joner G, Jenum PA, Eskild A, Torjesen PA, Stene LC: Maternal serum levels of 25-hydroxy-vitamin D during pregnancy and risk of type 1 diabetes in the offspring. *Diabetes* 2012;61:175-178
11. Cadario F, Savastio S, Pagliardini V, Bagnati M, Vidali M, Cerutti F, Rabbone I, Fontana F, Lera R, De Donno V, Valori A, Gruden G, Bona G, Bruno G: Vitamin D levels at birth and risk of type 1 diabetes in childhood: a case-control study. *Acta Diabetologica* 2015;52:1077-1081
12. Jacobsen R, Thorsen SU, Cohen AS, Lundqvist M, Frederiksen P, Pippert CB, Pociot F, Thygesen LC, Ascherio A, Svensson J, Heitmann BL: Neonatal vitamin D status is not associated with later risk of type 1 diabetes: results from two large Danish population-based studies. *Diabetologia* 2016;59:1871-1881
13. Raab J, Giannopoulou EZ, Schneider S, Warncke K, Krasmann M, Winkler C, Ziegler A-G: Prevalence of vitamin D deficiency in pre-type 1 diabetes and its association with disease progression. *Diabetologia* 2014;57:902-908
14. Reinert-Hartwall L, Honkanen J, Härkönen T, Ilonen J, Simell O, Peet A, Tillmann V, Lamberg-Allardt C, Virtanen SM, Knip M, Vaarala O, The DSG: No association between vitamin D and  $\beta$ -cell autoimmunity in Finnish and Estonian children. *Diabetes/Metabolism Res Rev* 2014;30:749-760
15. Mäkinen M, Mykkänen J, Koskinen M, Simell V, Veijola R, Hyöty H, Ilonen J, Knip M, Simell O, Toppari J: Serum 25-Hydroxyvitamin D Concentrations in Children Progressing to Autoimmunity and Clinical Type 1 Diabetes. *Journal Clin Endocrinol Metab* 2016;101:723-729

16. Munger KL, Levin LI, Massa J, Horst R, Orban T, Ascherio A: Preclinical serum 25-hydroxyvitamin D levels and risk of type 1 diabetes in a cohort of US military personnel. *Am J Epidemiol* 2013;177:411-419
17. Gorham ED, Garland CF, Burgi AA, Mohr SB, Zeng K, Hofflich H, Kim JJ, Ricordi C: Lower prediagnostic serum 25-hydroxyvitamin D concentration is associated with higher risk of insulin-requiring diabetes: a nested case-control study. *Diabetologia* 2012;55:3224-3227
18. The TEDDY Study Group: The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. *Pediatric Diabetes* 2007;8:286-298
19. Hagopian WA, Erlich H, Lernmark Å, Rewers M, Ziegler AG, Simell O, Akolkar B, Vogt R, Blair A, Ilonen J, Krischer J, She J, the TSG: The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. *Pediatric Diabetes* 2011;12:733-743
20. Bonifacio E, Yu L, Williams AK, Eisenbarth GS, Bingley PJ, Marcovina SM, Adler K, Ziegler AG, Mueller PW, Schatz DA, Krischer JP, Steffes MW, Akolkar B: Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. *J Clin Endocrinol Metab* 2010;95:3360-3367
21. Babaya N, Yu L, Miao D, Wang J, Rewers M, Nakayama M, Liu E, Barker JM, Eisenbarth GS: Comparison of insulin autoantibody: polyethylene glycol and micro-IAA 1-day and 7-day assays. *Diabetes Metab Res Rev* 2009;25:665-670
22. Lee H-S, Burkhardt BR, McLeod W, Smith S, Eberhard C, Lynch K, Hadley D, Rewers M, Simell O, She J-X, Hagopian B, Lernmark A, Akolkar B, Ziegler AG, Krischer JP, The Tsg: Biomarker discovery study design for type 1 diabetes in The Environmental Determinants of Diabetes in the Young (TEDDY) study. *Diabetes/Metabolism Res Rev* 2014;30:424-434
23. Dowling KG, Hull G, Sundvall J, Lamberg-Allardt C, Cashman KD: Improved accuracy of an tandem liquid chromatography-mass spectrometry method measuring 24R,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D metabolites in serum using unspiked controls and its application to determining cross-reactivity of a chemiluminescent microparticle immunoassay. *Journal of Chromatography A* 2017;1497:102-109
24. Borgan Ø, Zhang Y: Using cumulative sums of martingale residuals for model checking in nested case-control studies. *Biometrics* 2015;71:696-703
25. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA: The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. *J Clin Endocrinol Metab* 2011;96:53-58
26. Spiro A, Buttriss JL: Vitamin D: An overview of vitamin D status and intake in Europe. *Nutrition Bulletin* 2014;39:322-350
27. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP: Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2011;96
28. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Statist Soc B* 1995;57:289-300
29. Ziegler AG, Rewers M, Simell O, et al.: Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. *JAMA : the Journal of the American Medical Association* 2013;309:2473-2479

30. Uitterlinden AG, Fang Y, van Meurs JBJ, Pols HAP, van Leeuwen JPTM: Genetics and biology of vitamin D receptor polymorphisms. *Gene* 2004;338:143-156
31. Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang H, Haussler CA, Galligan MA, Thatcher ML, Dominguez CE, Haussler MR: Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. *Mol Cell Endocrinol* 2001;177:145-149
32. Lagunova Z, Porojnicu AC, Vieth R, Lindberg FA, Hexeberg S, Moan J: Serum 25-Hydroxyvitamin D Is a Predictor of Serum 1,25-Dihydroxyvitamin D in Overweight and Obese Patients. *J Nutrition* 2011;141:112-117
33. Engelman CD, Fingerlin TE, Langefeld CD, Hicks PJ, Rich SS, Wagenknecht LE, Bowden DW, Norris JM: Genetic and environmental determinants of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels in Hispanic and African Americans. *J Clin Endocrinol Metab* 2008;93:3381-3388
34. Zella LA, Kim S, Shevde NK, Pike JW: Enhancers located in the vitamin D receptor gene mediate transcriptional autoregulation by 1,25-dihydroxyvitamin D<sub>3</sub>. *J Steroid Biochem Molec Biology* 2007;103:435-439
35. Zella LA, Meyer MB, Nerenz RD, Lee SM, Martowicz ML, Pike JW: Multifunctional Enhancers Regulate Mouse and Human Vitamin D Receptor Gene Transcription. *Molec Endocrinol* 2010;24:128-147
36. Tizaoui K, Kaabachi W, Hamzaoui A, Hamzaoui K: Contribution of VDR polymorphisms to type 1 diabetes susceptibility: Systematic review of case-control studies and meta-analysis. *J Steroid Biochem Molec Biology* 2014;143:240-249
37. Young KA, Munroe ME, Guthridge JM, Kamen DL, Niewold TB, Gilkeson GS, Weisman MH, Ishimori ML, Kelly J, Gaffney PM, Sivils KH, Lu R, Wallace DJ, Karp DR, Harley JB, James JA, Norris JM: Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus. *Ann Rheumatic Dis* 2017;76:153-158
38. Levin GP, Robinson-Cohen C, de Boer IH, et al.: Genetic variants and associations of 25-hydroxyvitamin d concentrations with major clinical outcomes. *JAMA : the Journal of the American Medical Association* 2012;308:1898-1905
39. Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG, Colston KW: Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. *Eur J Cancer* 2005;41:1164-1169
40. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E: Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. *Prostate* 2007;67:911-923
41. Papadopoulou A, Kouis P, Middleton N, Kolokotroni O, Karpathios T, Nicolaidou P, Yiallourous PK: Association of vitamin D receptor gene polymorphisms and vitamin D levels with asthma and atopy in Cypriot adolescents: a case-control study. *Multidisciplinary Respiratory Medicine* 2015;10:26
42. Dankers W, Colin EM, van Hamburg JP, Lubberts E: Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential. *Frontiers in Immunology* 2017;7
43. Altieri B, Muscogiuri G, Barrea L, Mathieu C, Vallone CV, Mascitelli L, Bizzaro G, Altieri VM, Tirabassi G, Balercia G, Savastano S, Bizzaro N, Ronchi CL, Colao A, Pontecorvi A, Della Casa S: Does vitamin D play a role in autoimmune endocrine disorders? A proof of concept. *Rev Endocrine Metabolic Disorders* 2017:1-12

44. Giulietti A, Gysemans C, Stoffels K, van Etten E, Decallonne B, Overbergh L, Bouillon R, Mathieu C: Vitamin D deficiency in early life accelerates Type 1 diabetes in non-obese diabetic mice. *Diabetologia* 2004;47:451-462
45. Mathieu C: Vitamin D and diabetes: Where do we stand? *Diabetes Research and Clinical Practice* 2015;108:201-209
46. Walter M, Kaupper T, Adler K, Foersch J, Bonifacio E, Ziegler AG: No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. *Diabetes Care* 2010;33:1443-1448
47. Bizzarri C, Pitocco D, Napoli N, Di SE, Maggi D, Manfrini S, Suraci C, Cavallo MG, Cappa M, Ghirlanda G, Pozzilli P: No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial. *Diabetes Care* 2010;33:1962-1963
48. Huynh T, Greer RM, Nyunt O, Bowling F, Cowley D, Leong GM, Cotterill AM, Harris M: The association between ketoacidosis and 25(OH)-vitamin D3 levels at presentation in children with type 1 diabetes mellitus. *Pediatric Diabetes* 2009;10:38-43
49. Franchi B, Piazza M, Sandri M, Mazzei F, Maffei C, Boner AL: Vitamin D at the onset of type 1 diabetes in Italian children. *European journal of pediatrics* 2014;173:477-482
50. Al-Zubeidi H, Leon-Chi L, Newfield RS: Low vitamin D level in pediatric patients with new onset type 1 diabetes is common, especially if in ketoacidosis. *Pediatric Diabetes* 2016;17:592-598
51. Gallo S, Comeau K, Vanstone C, et al.: Effect of different dosages of oral vitamin d supplementation on vitamin d status in healthy, breastfed infants: A randomized trial. *JAMA : the Journal of the American Medical Association* 2013;309:1785-1792
52. Brett NR, Lavery P, Agellon S, Vanstone CA, Maguire JL, Rauch F, Weiler HA: Dietary vitamin D dose-response in healthy children 2 to 8 y of age: a 12-wk randomized controlled trial using fortified foods. *Am J Clin Nutr* 2016;103:144-152



**Table 1. Characteristics of subjects in the TEDDY Nested Case-Control Study**

Matching Variable	Number and % of Cases	Plasma 25(OH)D Concentration (nmol/L)			
		Mean $\pm$ SD			
		Childhood <sup>*</sup>		Early Infancy <sup>†</sup>	
		Cases	Controls	Cases	Controls
<b>Clinical Center</b>					
Colorado	55 (14.6%)	50.6 $\pm$ 17.8	56.1 $\pm$ 15.4	42.6 $\pm$ 25.7	44.8 $\pm$ 22.6
Georgia	23 (6.1%)	58.3 $\pm$ 20.0	59.3 $\pm$ 17.0	51.2 $\pm$ 21.8	53.7 $\pm$ 21.1
Washington State	35 (9.3%)	51.3 $\pm$ 14.6	56.1 $\pm$ 17.1	44.2 $\pm$ 18.7	46.7 $\pm$ 24.9
Finland	112 (29.8%)	43.1 $\pm$ 13.0	44.9 $\pm$ 13.7	41.1 $\pm$ 15.0	43.0 $\pm$ 15.8
Germany	29 (7.7%)	57.3 $\pm$ 23.1	65.0 $\pm$ 19.8	56.1 $\pm$ 29.9	64.1 $\pm$ 22.3
Sweden	122 (32.5%)	56.5 $\pm$ 14.6	59.5 $\pm$ 14.8	53.9 $\pm$ 20.3	60.4 $\pm$ 20.8
<b>Sex</b>					
Female	167 (44.4%)	51.7 $\pm$ 17.0	54.2 $\pm$ 17.2	47.5 $\pm$ 21.5	49.8 $\pm$ 22.0
Male	209 (55.6%)	51.0 $\pm$ 16.7	55.0 $\pm$ 16.4	47.3 $\pm$ 21.4	52.2 $\pm$ 21.6
<b>FDR/GP status</b>					
FDR	91 (24.2%)	47.4 $\pm$ 17.2	56.8 $\pm$ 17.3	42.5 $\pm$ 20.8	54.4 $\pm$ 23.3
GP	285 (75.8%)	52.6 $\pm$ 16.5	53.9 $\pm$ 16.5	48.9 $\pm$ 21.4	50.1 $\pm$ 21.2

<sup>\*</sup>Average of measures from all visits prior to and including the seroconversion visit, which is the first of two consecutive visits at which the child tested positive for an autoantibody.

<sup>†</sup>Defined by the first 25(OH)D measure, occurring before 12 months of age in 360 cases and their 981 controls.

FDR, first degree relative of an individual with type 1 diabetes

GP, from the general population (no first degree relative with type 1 diabetes)

**Table 2. Association between 25(OH)D Concentration and Vitamin D Sufficiency and Islet Autoimmunity in the TEDDY Nested Case-Control Study.**

Vitamin D Measure	All Cases (n=376) and Controls (n=1041)	Cases with Multiple Autoantibodies (n= 230) and Controls (n=639)
Childhood 25(OH)D concentration <sup>†</sup> (per 5 nmol/L increase)	0.93 (0.89-0.97)	0.91 (0.87-0.96)
Early infancy 25(OH)D concentration <sup>‡</sup> (per 5 nmol/L increase)	0.94 (0.91-0.98)	0.93 (0.89-0.97)
Childhood Vitamin D Sufficiency <sup>†</sup> ( $\geq 50$ versus $< 50$ nmol/L)	0.68 (0.52-0.89)	0.61 (0.43-0.86)
Early infancy Vitamin D Sufficiency <sup>‡</sup> ( $\geq 50$ versus $< 50$ nmol/L)	0.59 (0.44-0.79)	0.57 (0.40-0.83)

\*Separate conditional logistic regression models were run for each vitamin D variable, adjusting for HLA-DR3/4 status and the first two PCs indicating ancestry. For the early infancy vitamin D measures, we also adjusted for age and season of sample collection at the first visit.

<sup>†</sup>Average of all visits prior to and including the seroconversion visit.

<sup>‡</sup>Defined by the first 25(OH)D measure, occurring before 12 months of age in 360 cases and their 981 controls. There were 220 cases with multiple autoantibodies, with their 603 controls with a measure before 12 months of age.

**Table 3. Test for Interaction Between Vitamin D Gene SNPs and the 25(OH)D variables on Risk of Islet Autoimmunity**

Gene	SNP (minor allele)	Minor Allele Frequency	Nominal P-value (P-value adjusted by false discovery rate)* for SNP Interaction with:			
			Childhood <sup>†</sup> 25(OH)D Concentration	Early Infancy <sup>‡</sup> 25(OH)D Concentration	Childhood Vitamin D Sufficiency	Early Infancy Vitamin D Sufficiency
<i>GC</i>	rs7041 (T)	0.42	0.67(0.96)	0.20 (0.60)	0.19 (0.34)	0.15 (0.45)
<i>CYP27B1</i>	rs4646536 (C)	0.33	0.29 (0.70)	0.93 (0.96)	0.46 (0.59)	0.52 (0.71)
<i>CYP24A1</i>	rs4809959 (A)	0.50	0.51(0.92)	0.96 (0.96)	0.04 (0.12)	0.63 (0.71)
<i>CYP24A1</i>	rs2616277 (A)	0.17	0.85 (0.96)	0.62 (0.80)	0.61(0.61)	0.83 (0.83)
<i>VDR</i> (Bsm1)	rs1544410 (A)	0.39	0.23 (0.70)	0.03 (0.14)	0.18 (0.34)	0.15 (0.45)
<i>VDR</i> (Apa1)	rs7975232 (C)	0.46	0.0072 (0.06)	0.0019 (0.017)	0.01(0.09)	0.0051(0.046)
<i>VDR</i> (Cdx2)	rs11568820 (A)	0.19	0.31(0.70)	0.51 (0.77)	0.04(0.12)	0.61(0.71)
<i>RXRa</i>	rs3818740 (C)	0.29	0.91(0.96)	0.47 (0.77)	0.41(0.59)	0.31(0.56)
<i>RXRa</i>	rs10881582 (A)	0.25	0.96 (0.96)	0.28 (0.63)	0.56(0.61)	0.21(0.47)

\*The nominal p-value of the interaction term is from the Wald test. In parentheses, we provide the p-value corrected by the false discovery rate.(28)


<sup>†</sup>Average of measures from all visits prior to and including the seroconversion visit.

<sup>‡</sup>The first 25(OH)D measure, occurring before 12 months of age in 360 cases and their 981 controls.

All models include HLA-DR3/4 status and the first two PCs indicating ancestry. For the early infancy vitamin D exposures, we also adjusted for age and season of sample collection at the first visit.

**Figure Legend**

**Figure 1.** Odds ratios and 95% confidence intervals for decreased risk of IA associated with 25(OH)D concentration (5 nmol/L increase) and being vitamin D sufficient ( $\geq 50$ nmol/L) versus insufficient by number of minor alleles (the C allele) at rs7975232 in the vitamin D receptor gene. Analyses are adjusted for HLA-DR3/4 and the first two PCs indicating ancestry; and odds ratios are calculated from the SNP\*vitamin D measure interaction terms. For childhood vitamin D measures, we analyzed 376 cases and their controls (297 cases with 3 controls, 71 cases with 2 controls and 8 cases with 1 control) with complete plasma 25(OH)D and vitamin D genetic data. For the early infancy vitamin D measures we analyzed 360 cases and their controls (269 cases with 3 controls, 83 cases with 2 controls and 8 cases with 1 control).



Odds ratios and 95% confidence intervals for decreased risk of IA associated with 25(OH)D concentration (5 nmol/L increase) and being vitamin D sufficient ( $\geq 50$ nmol/L) versus insufficient by number of minor alleles (the C allele) at rs7975232 in the vitamin D receptor gene. Analyses are adjusted for HLA-DR3/4 and the first two PCs indicating ancestry; and odds ratios are calculated from the SNP\*vitamin D measure interaction terms. For childhood vitamin D measures, we analyzed 376 cases and their controls (297 cases with 3 controls, 71 cases with 2 controls and 8 cases with 1 control) with complete plasma 25(OH)D and vitamin D genetic data. For the early infancy vitamin D measures we analyzed 360 cases and their controls (269 cases with 3 controls, 83 cases with 2 controls and 8 cases with 1 control).

223x218mm (300 x 300 DPI)

**Online Appendix**

**Supplemental Table 1. Predictors of 25(OH)D Concentration in Controls from the TEDDY Nested Case-Control Study Using a Linear Mixed Effects Model.**

Using a linear mixed effects model for a subject-specific 25(OH)D concentration, season and year of blood draw, height and weight of the child at blood draw, whether or not the child was on the LDP (i.e., sample collected locally and shipped to a TEDDY clinical center for processing), and sample set were significantly associated with 25(OH)D concentration among controls.

Potential Predictor	Units, if continuous, or Category, if categorical	Parameter Estimate (Standard error)	p-value
Age	In months	0.04(0.11)	0.72
Height	In cm	0.31(0.14)	0.026
Weight	In kg	-1.29(0.43)	0.003
Season of Blood Draw	Spring (March-May)	-0.19(0.73)	0.79
	Summer (June-August)	5.37(0.73)	<0.0001
	Fall (September-November)	4.99(0.75)	<0.0001
	Winter (Dec-Feb)	Ref	
Year of Blood Draw	2004-2005	-10.0(2.67)	0.0002
	2006	-6.35(2.37)	0.007
	2007	-5.35(2.23)	0.016
	2008	-3.85(2.14)	0.07
	2009	-1.73(2.03)	0.40
	2010	-1.13(1.95)	0.56
	2011-2012	Ref	
Long distance protocol (LDP)	Yes	4.98(1.22)	<0.0001
	No	Ref	
Sample Set	Set 2 (6 month, 12 month and later samples)	3.96(0.55)	<0.0001
	Set 1 (3 month and 9 month samples)	Ref	

**Supplemental Table 2. Association between 25(OH)D Concentration Categories and Islet Autoimmunity in the TEDDY Nested Case-Control Study.**

Vitamin D Measure	All Cases (n=376) and Controls (n=1041)	Cases with Multiple Autoantibodies (n= 230) and Controls (n=639)
OR (95% CI)*		
Childhood 25(OH) concentration <sup>†</sup>		
>75 nmol/L	0.52 (0.32-0.84)	0.44 (0.23-0.84)
50-75 nmol/L	0.71 (0.54-0.93)	0.64 (0.45-0.91)
< 50 nmol/L	1.0 (ref)	1.0 (ref)
Early infancy 25(OH)D concentration <sup>‡</sup>		
>75 nmol/L	0.54 (0.33-0.86)	0.54 (0.29-0.99)
50-75 nmol/L	0.61 (0.45-0.82)	0.58 (0.40-0.85)
< 50 nmol/L	1.0 (ref)	1.0 (ref)

\*Separate conditional logistic regression models were run for each vitamin D variable, adjusting for HLA-DR3/4 status and the first two PCs indicating ancestry. For the early infancy vitamin D measures, we also adjusted for age and season of sample collection at the first visit.

<sup>†</sup>Average of all visits prior to and including the seroconversion visit.

<sup>‡</sup>Defined by the first 25(OH)D measure, occurring before 12 months of age in 360 cases and their 981 controls. There were 220 cases with multiple autoantibodies and their 603 controls with a first measure before 12 months of age.



### **The Teddy Study Group**

**Colorado Clinical Center:** Marian Rewers, M.D., Ph.D., PI<sup>1,4,5,6,10,11</sup>, Kimberly Bautista<sup>12</sup>, Judith Baxter<sup>9,10,12,15</sup>, Ruth Bedoy<sup>2</sup>, Daniel Felipe-Morales, Kimberly Driscoll, Ph.D.<sup>9</sup>, Brigitte I. Frohnert, M.D.<sup>2,14</sup>, Patricia Gesualdo<sup>2,6,12,14,15</sup>, Michelle Hoffman<sup>12,13,14</sup>, Rachel Karban<sup>12</sup>, Edwin Liu, M.D.<sup>13</sup>, Jill Norris, Ph.D.<sup>2,3,12</sup>, Adela Samper-Imaz, Andrea Steck, M.D.<sup>3,14</sup>, Kathleen Waugh<sup>6,7,12,15</sup>, Hali Wright<sup>12</sup>. University of Colorado, Anschutz Medical Campus, Barbara Davis Center for Childhood Diabetes.

**Finland Clinical Center:** Jorma Toppari, M.D., Ph.D., PI<sup>¥^1,4,11,14</sup>, Olli G. Simell, M.D., Ph.D.<sup>¥^1,4,11,13</sup>, Annika Adamsson, Ph.D.<sup>^12</sup>, Suvi Ahonen<sup>\*±§</sup>, Heikki Hyöty, M.D., Ph.D.<sup>\*±6</sup>, Jorma Ilonen, M.D., Ph.D.<sup>¥^13</sup>, Sanna Jokipuu<sup>^</sup>, Tiina Kallio<sup>^</sup>, Leena Karlsson<sup>^</sup>, Miia Kähönen<sup>μ□</sup>, Mikael Knip, M.D., Ph.D.<sup>\*±5</sup>, Lea Kovanen<sup>\*±§</sup>, Mirva Koreasalo<sup>\*±§2</sup>, Kalle Kurppa, M.D., Ph.D.<sup>\*±13</sup>, Tiina Latva-aho<sup>μ□</sup>, Maria Lönnrot, M.D., Ph.D.<sup>\*±6</sup>, Elina Mäntymäki<sup>^</sup>, Katja Multasuo<sup>μ□</sup>, Juha Mykkänen, Ph.D.<sup>¥^3</sup>, Tiina Niininen<sup>\*±12</sup>, Sari Niinistö<sup>±§</sup>, Mia Nyblom<sup>\*±</sup>, Petra Rajala<sup>^</sup>, Jenna Rautanen<sup>±§</sup>, Anne Riikonen<sup>\*±§</sup>, Mika Riikonen<sup>^</sup>, Jenni Rouhiainen<sup>^</sup>, Minna Romo<sup>^</sup>, Tuula Simell, Ph.D., Ville Simell<sup>¥^13</sup>, Maija Sjöberg<sup>¥^12,14</sup>, Aino Stenius<sup>μ□12</sup>, Maria Leppänen<sup>^</sup>, Sini Vainionpää<sup>^</sup>, Eeva Varjonen<sup>¥^12</sup>, Riitta Veijola, M.D., Ph.D.<sup>μ□14</sup>, Suvi M. Virtanen, M.D., Ph.D.<sup>\*±§2</sup>, Mari Vähä-Mäkilä<sup>^</sup>, Mari Åkerlund<sup>\*±§</sup>, Katri Lindfors, Ph.D.<sup>\*13</sup>  
 ¥University of Turku, \*University of Tampere, μUniversity of Oulu, ^Turku University Hospital, Hospital District of Southwest Finland, ±Tampere University Hospital, □Oulu University Hospital, §National Institute for Health and Welfare, Finland, ¶University of Kuopio.

**Georgia/Florida Clinical Center:** Jin-Xiong She, Ph.D., PI<sup>1,3,4,11</sup>, Desmond Schatz, M.D.<sup>\*4,5,7,8</sup>, Diane Hopkins<sup>12</sup>, Leigh Steed<sup>12,13,14,15</sup>, Jamie Thomas<sup>\*6,12</sup>, Janey Adams<sup>\*12</sup>, Katherine Silvis<sup>2</sup>, Michael Haller, M.D.<sup>\*14</sup>, Melissa Gardiner, Richard McIndoe, Ph.D., Ashok Sharma, Joshua Williams, Gabriela Young, Stephen W. Anderson, M.D.<sup>^</sup>, Laura Jacobsen, M.D.<sup>\*14</sup> Center for Biotechnology and Genomic Medicine, Augusta University. \*University of Florida, ^Pediatric Endocrine Associates, Atlanta.

**Germany Clinical Center:** Anette G. Ziegler, M.D., PI<sup>1,3,4,11</sup>, Andreas Beyerlein, Ph.D.<sup>2</sup>, Ezio Bonifacio Ph.D.<sup>\*5</sup>, Michael Hummel, M.D.<sup>13</sup>, Sandra Hummel, Ph.D.<sup>2</sup>, Kristina Foterek<sup>¥2</sup>, Nicole Janz, Mathilde Kersting, Ph.D.<sup>¥2</sup>, Annette Knopff<sup>7</sup>, Sibylle Koletzko, M.D.<sup>¶13</sup>, Claudia Peplow<sup>12</sup>, Roswith Roth, Ph.D.<sup>9</sup>, Marlon Scholz, Joanna Stock<sup>9,12,14</sup>, Katharina Warncke, M.D.<sup>14</sup>, Lorena Wendel, Christiane Winkler, Ph.D.<sup>2,12,15</sup>. Forschergruppe Diabetes e.V. and Institute of Diabetes Research, Helmholtz Zentrum München, and Klinikum rechts der Isar, Technische Universität München. \*Center for Regenerative Therapies, TU Dresden, ¶Dr. von Hauner Children's Hospital, Department of Gastroenterology, Ludwig Maximilians University Munich, ¥Research Institute for Child Nutrition, Dortmund.

**Sweden Clinical Center:** Åke Lernmark, Ph.D., PI<sup>1,3,4,5,6,8,10,11,15</sup>, Daniel Agardh, M.D., Ph.D.<sup>13</sup>, Carin Andrén Aronsson<sup>2,12,13</sup>, Maria Ask, Jenny Bremer, Ulla-Marie Carlsson, Corrado Cilio,

Ph.D., M.D.<sup>5</sup>, Emelie Ericson-Hallström, Lina Fransson, Thomas Gard, Joanna Gerardsson, Rasmus Bennet, Monica Hansen, Gertie Hansson, Susanne Hyberg, Fredrik Johansen, Berglind Jonsdottir, M.D., Helena Elding Larsson, M.D., Ph.D.<sup>6,14</sup>, Marielle Lindström, Markus Lundgren, M.D.<sup>14</sup>, Maria Månsson-Martinez, Maria Markan, Jessica Melin<sup>12</sup>, Zeliha Mestan, Karin Ottosson, Kobra Rahmati, Anita Ramelius, Falastin Salami, Sara Sibthorpe, Birgitta Sjöberg, Ulrica Swartling, Ph.D.<sup>9,12</sup>, Evelyn Tekum Amboh, Carina Törn, Ph.D.<sup>3,15</sup>, Anne Wallin, Åsa Wimar<sup>12,14</sup>, Sofie Åberg. Lund University.

**Washington Clinical Center:** William A. Hagopian, M.D., Ph.D., PI<sup>1,3,4, 5, 6,7,11,13, 14</sup>, Michael Killian<sup>6,7,12,13</sup>, Claire Cowen Crouch<sup>12,14,15</sup>, Jennifer Skidmore<sup>2</sup>, Josephine Carson, Maria Dalzell, Kayleen Dunson, Rachel Hervey, Corbin Johnson, Rachel Lyons, Arlene Meyer, Denise Mulenga, Alexander Tarr, Morgan Uland, John Willis. Pacific Northwest Diabetes Research Institute.

**Pennsylvania Satellite Center:** Dorothy Becker, M.D., Margaret Franciscus, MaryEllen Dalmagro-Elias Smith<sup>2</sup>, Ashi Daftary, M.D., Mary Beth Klein, Chrystal Yates. Children's Hospital of Pittsburgh of UPMC.

**Data Coordinating Center:** Jeffrey P. Krischer, Ph.D., PI<sup>1,4,5,10,11</sup>, Michael Abbondandolo, Sarah Austin-Gonzalez, Maryouri Avendano, Sandra Baethke, Rasheedah Brown<sup>12,15</sup>, Brant Burkhardt, Ph.D.<sup>5,6</sup>, Martha Butterworth<sup>2</sup>, Joanna Clasen, David Cuthbertson, Christopher Eberhard, Steven Fiske<sup>9</sup>, Dena Garcia, Jennifer Garmeson, Veena Gowda, Kathleen Heyman, Francisco Perez Laras, Hye-Seung Lee, Ph.D.<sup>1,2,13,15</sup>, Shu Liu, Xiang Liu, Ph.D.<sup>2,3,9,14</sup>, Kristian Lynch, Ph.D.<sup>5,6,9,15</sup>, Jamie Malloy, Cristina McCarthy<sup>12,15</sup>, Steven Meulemans, Hemang Parikh, Ph.D.<sup>3</sup>, Chris Shaffer, Laura Smith, Ph.D.<sup>9,12</sup>, Susan Smith<sup>12,15</sup>, Noah Sulman, Ph.D., Roy Tamura, Ph.D.<sup>1,2,13</sup>, Ulla Uusitalo, Ph.D.<sup>2,15</sup>, Kendra Vehik, Ph.D.<sup>4,5,6,14,15</sup>, Ponni Vijayakandipan, Keith Wood, Jimin Yang, Ph.D., R.D.<sup>2,15</sup>. *Past staff: Lori Ballard, David Hadley, Ph.D., Wendy McLeod.* University of South Florida.

**Project scientist:** Beena Akolkar, Ph.D.<sup>1,3,4,5,6,7,10,11</sup>. National Institutes of Diabetes and Digestive and Kidney Diseases.

**Other contributors:** Kasia Bourcier, Ph.D.<sup>5</sup>, National Institutes of Allergy and Infectious Diseases. Thomas Briese, Ph.D.<sup>6,15</sup>, Columbia University. Suzanne Bennett Johnson, Ph.D.<sup>9,12</sup>, Florida State University. Eric Triplett, Ph.D.<sup>6</sup>, University of Florida.

**Autoantibody Reference Laboratories:** Liping Yu, M.D.<sup>^5</sup>, Dongmei Miao, M.D.<sup>^</sup>, Polly Bingley, M.D., FRCP<sup>\*5</sup>, Alistair Williams\*, Kyla Chandler\*, Saba Rokni\*, Claire Williams\*, Rebecca Wyatt\*, Gifty George\*, Sian Grace\*. <sup>^</sup>Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, \*School of Clinical Sciences, University of Bristol UK.

**Dietary Biomarkers Laboratory:** Iris Erlund, Ph.D.<sup>2</sup>, Irma Salminen, Jouko Sundvall, Jaana Leiviskä, Nina Kangas, Petra Arohonka. National Institute for Health and Welfare, Helsinki, Finland.

**HLA Reference Laboratory:** Henry Erlich, Ph.D.<sup>3</sup>, Steven J. Mack, Ph.D., Anna Lisa Fear. Center for Genetics, Children's Hospital Oakland Research Institute.

**Repository:** Sandra Ke, Niveen Mulholland, Ph.D. NIDDK Biosample Repository at Fisher BioServices.

**SNP Laboratory:** Stephen S. Rich, Ph.D.<sup>3</sup>, Wei-Min Chen, Ph.D.<sup>3</sup>, Suna Onengut-Gumuscu, Ph.D.<sup>3</sup>, Emily Farber, Rebecca Roche Pickin, Ph.D., Jordan Davis, Dan Gallo, Jessica Bonnie, Paul Campolieto. Center for Public Health Genomics, University of Virginia.

***Committees:***

<sup>1</sup>Ancillary Studies, <sup>2</sup>Diet, <sup>3</sup>Genetics, <sup>4</sup>Human Subjects/Publicity/Publications, <sup>5</sup>Immune Markers, <sup>6</sup>Infectious Agents, <sup>7</sup>Laboratory Implementation, <sup>8</sup>Maternal Studies, <sup>9</sup>Psychosocial, <sup>10</sup>Quality Assurance, <sup>11</sup>Steering, <sup>12</sup>Study Coordinators, <sup>13</sup>Celiac Disease, <sup>14</sup>Clinical Implementation, <sup>15</sup>Quality Assurance Subcommittee on Data Quality.